America's premier infectious disease agency is effectively leaderless — and it's happening in the middle of an active Ebola outbreak.

America's premier infectious disease agency is effectively leaderless — and it's happening in the middle of an active Ebola outbreak.

Dr. Jeffrey Taubenberger, acting director of the National Institute of Allergy and Infectious Diseases, has stepped down. He is the latest in a sweeping leadership exodus, eight of the top ten senior NIAID officials have now been pushed out or reassigned since President Trump took office. His departure was barely announced. (WHO)

Taubenberger's exit only became publicly known when Senator Tammy Baldwin disclosed during a Senate Appropriations Committee hearing that he would not be testifying as scheduled, a conspicuous absence for the man leading one of NIH's most powerful institutes. (TODAY.com)

The vacancy extends far beyond one agency. America currently has no confirmed Surgeon General, no FDA Commissioner, no CDC Director, and no Deputy Secretary of Health and Human Services. Across NIH broadly, 16 of its 27 institutes and centers currently lack permanent directors. (National Academy of Medicine)

NIAID's role is critical, it evaluates treatment and prevention options for a wide range of diseases, determines which research gets funded, and decides which vaccines are developed. Without stable leadership, that function is paralyzed. (CDC)

Senators on both sides raised alarms. Senator Patty Murray warned directly: "It just seems to me we have dismantled our infectious disease research and development pipeline, and we will pay the price." (Wikipedia)

NIH Director Jay Bhattacharya defended the changes, saying the agency is shifting focus. "We have shifted the focus of NIAID to address diseases and conditions that people actually have, including hantavirus and Ebola," he said, adding that the departures reflect a change in mission rather than a dismantling of capacity. (CDC)

Critics aren't convinced. With Ebola surpassing 1,000 cases in Central Africa and hantavirus emerging domestically, the question isn't whether NIAID needed reform. It's whether gutting its leadership mid-outbreak was the right moment to find out.